Early Menopause Test: Which Labs Confirm The Diagnosis

An early menopause test is a blood draw that measures follicle-stimulating hormone (FSH) to confirm whether ovarian function has declined before the expected age. Premature menopause, defined as the final menstrual period before age 40, and early menopause, defined as the final period between ages 40 and 45, both typically involve laboratory confirmation (Panay et al., 2024). A home urine kit can't substitute for this workup. The diagnosis starts with cycle history, moves to serum FSH and estradiol, and then branches into cause-specific testing when the results point to premature ovarian insufficiency (POI).

Women who suspect their cycles are changing earlier than expected can order blood work directly without waiting for a referral. Serum FSH is the primary biochemical marker. If drawn while a woman is under 40 and has had at least 4 months of absent or irregular cycles, a single FSH above 25 IU/L meets the current international diagnostic threshold (Panay et al., 2024). That threshold changed in December 2024, and the shift matters for anyone comparing older test guidance to current practice.

Early menopause testing involves a serum FSH measurement alongside estradiol, pregnancy exclusion, and thyroid function. When FSH is above 25 IU/L in a woman under 40 with at least 4 months of cycle disruption, the 2024 international guideline supports the diagnosis without a mandatory repeat draw.

Blood vials for FSH and estradiol early menopause testing

When Should You Get Tested For Early Menopause?

Testing makes sense only in certain age and symptom combinations. Not every missed period calls for a hormone panel.

For women under 40 with 4 or more months of absent or irregular cycles, serum FSH is indicated. This is the group where the early menopause test carries clinical weight, because the finding changes management: it triggers further workup for chromosomal, autoimmune, and genetic causes, and it opens a conversation about hormone therapy and bone protection (Panay et al., 2024).

For women aged 40 to 45 with symptoms and cycle changes, FSH testing is still reasonable. The British Menopause Society and NICE NG23 support FSH in this age band, though some guidance still calls for 2 draws 4 to 6 weeks apart rather than one (NICE, 2024).

For women 45 and older with typical symptoms (hot flashes, night sweats, vaginal dryness, irregular periods), guidelines from NICE and the 2024 international group say do not order confirmatory laboratory tests. Menopause in this group is a clinical diagnosis based on symptoms alone (NICE, 2024). A normal FSH doesn't rule out perimenopause, because FSH swings during the transition. Buying a menopause panel for confirmation at age 48 with classic symptoms is unnecessary under current guidelines.

Before any hormonal blood draw, pregnancy must be excluded. Combined hormonal contraception suppresses FSH and makes results uninterpretable. Providers typically advise stopping hormonal contraception and waiting before ordering FSH, because these methods suppress FSH and make results uninterpretable.

Which Blood Tests Are Used In An Early Menopause Test?

The core panel is shorter than consumer marketing suggests. Five markers cover the initial workup; 2 more follow only if POI is confirmed.

FSH is the primary test. A serum FSH measurement above 25 IU/L in a woman under 40 with cycle disruption meets the 2024 international threshold. Older U.S. guidance from ACOG (2014) used a higher bar, typically above 30 to 40 mIU/mL on 2 separate draws at least 1 month apart (ACOG, 2014). Both rules are still in circulation. The units IU/L and mIU/mL are the same for FSH.

Estradiol supports the FSH finding but doesn't confirm POI on its own. A low estradiol paired with a high FSH strengthens the case. A sensitive estradiol test reads low-range values more accurately than a standard assay, which matters when estradiol is near or below 30 pg/mL.

Two markers exist to exclude other causes. An hCG pregnancy test must come first, because pregnancy is excluded before FSH is interpreted. A thyroid function test (TSH) screens for thyroid disease, which can mimic early menopause symptoms. Irregular cycles, fatigue, mood changes, and weight shifts overlap between the 2 conditions.

High prolactin is a separate cause of amenorrhea that has nothing to do with ovarian failure. When prolactin rises, it can suppress FSH and LH, stopping cycles without any loss of ovarian reserve. Ruling it out prevents a misread of the FSH result.

AMH (anti-Mullerian hormone) is where consumer marketing parts ways with guideline evidence. The 2024 guideline issued a strong recommendation against using AMH routinely to confirm POI or to predict the timing of menopause (Panay et al., 2024). AMH tracks follicle count, but accuracy is insufficient for individual prediction. A 2023 analysis of 27 direct-to-consumer AMH websites found most made claims about fertility prediction or menopause timing that evidence doesn't support (Johnson et al., 2023). AMH may help only when FSH results are inconclusive, and only in clinical context.

For confirmed POI (non-iatrogenic, under 40), the workup expands to karyotype analysis and FMR1 premutation testing, plus autoimmune screening including adrenal and thyroid antibodies. These aren't part of a consumer hormone panel. They require a provider's order and genetic counseling.

Marek Diagnostics lists each of these markers under individual biomarkers, and the lab bundles collection pairs related hormones together. Results should be reviewed with a licensed clinician, since the numbers mean different things depending on age, contraceptive use, and cycle timing.

How The Diagnostic Criteria Changed In 2024

The 2024 evidence-based guideline from ESHRE, the International Menopause Society, ASRM, and the Monash Centre for Research Excellence changed 2 things that affect how an early menopause test is read (Panay et al., 2024).

First, the FSH threshold dropped. The prior ACOG standard used FSH above 30 to 40 mIU/mL. The 2024 international guideline uses FSH above 25 IU/L. A woman whose FSH sits at 28 IU/L would have been told she was "normal" under the older rule and "consistent with POI" under the current one.

Second, the repeat-test requirement was loosened. The 2015 ESHRE guideline and the 2014 ACOG committee opinion both required 2 FSH results above the threshold. The 2024 update says 1 high FSH is enough if the clinical picture fits (4 or more months of amenorrhea or irregular cycles in a woman under 40). A repeat is needed only when the diagnosis remains uncertain.

These changes were made to shorten diagnostic delay. The guideline group noted that women with POI often waited months to years for confirmation under the 2-test rule. The intent is faster access to cause-specific workup and, when appropriate, hormone therapy.

ACOG has not published a matching revision as of mid-2026. A woman whose provider follows ACOG 2014 guidance may still be asked for 2 draws. A woman whose provider follows the 2024 international criteria needs only 1. Both are defensible. What matters is knowing which rule your result was read against.

Woman ordering a direct-access menopause blood test online

Can A Home Test Diagnose Early Menopause?

No. A urine FSH dipstick is a screening tool, not a diagnostic test.

Most over-the-counter menopause kits measure urine FSH against a cutoff near 25 mIU/mL. They give a qualitative result (above the cutoff or not). They don't measure the exact level, they don't account for cycle-day variation, and they don't exclude the 5 or 6 other conditions that can raise FSH or stop cycles.

No urine FSH kit sold in the U.S. carries FDA authorization as an early menopause or POI diagnostic. The only FDA-authorized menopause-related blood test is the PicoAMH ELISA (Ansh Labs), permitted in October 2018 as an aid in determining menopausal status in women aged 42 to 62 (FDA, 2018). That authorization doesn't cover women under 40, doesn't cover urine kits, and came with a warning against stopping contraception based on the result alone.

A positive home test may be the prompt that sends someone to a provider. That part is useful. The danger is treating a urine dipstick as a diagnosis, stopping contraception, or skipping the serum workup that would catch a treatable cause of amenorrhea.

Testing Approach	What It Measures	Turnaround	Clinical Depth	Main Limitation
Urine FSH home kit	Qualitative urine FSH	Same day	None	Not a POI diagnosis; fluctuates with cycle
Provider-ordered serum panel	FSH, estradiol, hCG, TSH, prolactin	Days	Full initial workup	Unreliable on hormonal contraception
Direct-access serum testing	Same serum markers	Days	Lab results with clinician review	Needs a provider for cause-specific workup
Reproductive endocrinology referral	Serum FSH plus karyotype, FMR1, adrenal antibodies	Weeks	Full POI evaluation	Required only for confirmed POI under 40

A 2025 editorial in the BMJ argued that commercial menopause panels add a false sense of precision, because no established therapeutic window exists for adjusting hormone therapy doses from panel results (Christakis et al., 2025). The editorial reinforced that saliva and urine methods are not the guideline specimen, and that over-45 testing for typical symptoms is unnecessary under current practice standards.

What Health Risks Follow Early Menopause?

The reason an early menopause test matters beyond the diagnosis itself is the long-term risk profile. More years without estrogen is associated with higher rates of several conditions, and identifying the change sooner may support earlier treatment decisions with a provider.

Cardiovascular disease risk is higher in observational data. A pooled analysis of over 310,000 women found that menopause before age 45 was associated with a relative risk of 1.50 (95% CI 1.28 to 1.76) for coronary heart disease and 1.19 (1.08 to 1.31) for cardiovascular mortality compared to menopause at 45 or later (Muka et al., 2016). Premature menopause (under 40) carried a hazard ratio of 1.55 (1.38 to 1.73) for incident cardiovascular disease versus menopause at age 50 to 51 (Zhu et al., 2019).

Bone density tends to decline faster when estrogen drops early. Osteoporosis screening and, in many cases, hormone therapy may be recommended as part of the management plan.

Cognitive and affective risks are less settled. The 2024 guideline acknowledges associations between early estrogen loss and cognitive or mood symptoms but stops short of calling them causal.

A test doesn't treat these risks. Hormone therapy until the average age of natural menopause is what the Menopause Society recommends for women with POI and premature or early menopause, unless a contraindication exists (Menopause Society, 2022). That decision is made with a provider, not from a panel result.

Does Early Menopause Affect Fertility?

POI is not always permanent sterility. Intermittent ovarian function can return. The 2024 guideline notes that spontaneous conception rates of 5 to 10% have been reported in women with POI, which means contraception is still relevant until a clinician confirms it isn't (Panay et al., 2024).

A single early menopause test that says "menopause" can lead someone to stop contraception. The FDA made this exact warning when it authorized the PicoAMH test: do not stop contraception based on a test result alone.

For women who want to conceive, a fertility specialist can discuss options that may include IVF with donor eggs, use of previously frozen eggs, and adoption. Fertility counseling is part of the POI workup under the 2024 guideline, not an afterthought.

The prevalence of POI has been reported at about 1 in 100 by age 40 in earlier population estimates (Coulam et al., 1986). More recent meta-analyses put the pooled figure at 3.5% (Li et al., 2023). Early menopause (40 to 45) is more common, with a pooled prevalence of 12.2% (Golezar et al., 2019). The difference between the older and newer numbers reflects broader definitions, better ascertainment, and inclusion of iatrogenic causes.

An early menopause test is the first step in separating normal menopause timing from premature ovarian insufficiency. The test itself is a serum FSH draw, read against cycle history and age. Home kits screen but don't diagnose. The 2024 guideline lowered the threshold and loosened the repeat requirement to shorten the path from symptom to confirmed diagnosis. What follows the test, the cause workup, the risk assessment, and the treatment conversation, is where clinical value sits. Building your panel is the starting point.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs

Can a home test diagnose early menopause?

No. Home kits measure urine FSH qualitatively and are not authorized as a diagnostic for early menopause or POI. The 2024 international guideline requires serum FSH above 25 IU/L plus at least 4 months of cycle disruption before age 40 (Panay et al., 2024). A urine dipstick doesn't meet that standard.

Do I need 2 FSH tests or 1?

Both rules exist. The 2024 ESHRE, IMS, and ASRM guideline says 1 FSH above 25 IU/L is enough when cycle history and age fit the picture. ACOG's 2014 committee opinion still calls for 2 draws at least 1 month apart. The answer depends on which standard your provider follows.

Does a normal FSH mean I am not in perimenopause?

Not necessarily. FSH fluctuates during the menopausal transition, and a single normal result doesn't rule out perimenopause. NICE NG23 states that at age 45 and older with typical symptoms, menopause is diagnosed from symptoms alone without confirmatory labs (NICE, 2024).

Should I test AMH to see if menopause is coming early?

The 2024 guideline recommends against using AMH as the primary diagnostic test for POI. AMH tracks follicle count but doesn't accurately predict the age of menopause in an individual (Panay et al., 2024). A 2023 review found most consumer AMH sites made claims the evidence doesn't support (Johnson et al., 2023).

Does early menopause raise heart disease risk?

Observational data suggest higher cardiovascular risk. A meta-analysis of over 310,000 women found roughly 50% higher relative risk of coronary heart disease and 19% higher cardiovascular mortality when menopause occurred before 45 versus 45 or later (Muka et al., 2016). These are associations, not proof that a test alone changes the outcome.

If the test is positive, do I still need birth control?

Yes, until menopause is confirmed and a provider advises otherwise. POI can include intermittent ovulation, and the FDA warned against stopping contraception based on a test result alone when it authorized the PicoAMH test (FDA, 2018).

What other tests are needed if FSH is high before 40?

Beyond FSH, the initial workup includes pregnancy exclusion, TSH, prolactin, and estradiol. For confirmed non-iatrogenic POI, the 2024 guideline calls for karyotype analysis and FMR1 premutation testing, plus autoimmune screening for adrenal and thyroid disease (Panay et al., 2024).

Your cart is currently empty.